{"id":"6da252f28a31","type":"article","url":"https://hartvaat.nl/2026/10/31/dapagliflozin-geassocieerd-met-minder-urineweginfecties-dan-empagliflozin-bij-di/","title":"Dapagliflozin geassocieerd met minder urineweginfecties dan empagliflozin bij diabetische vrouwen","title_en":"Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"International journal of endocrinology and metabolism","doi":"10.5812/ijem-168824","source_url":"https://doi.org/10.5812/ijem-168824","authors":["Sara Kazem-Nadi","Sara Keshtkari","Zohre Labbani-Motlagh","Vahid Mousavi"],"significance":5,"published":"2026-09-28","source_date":"2026-10-31","image":"https://hartvaat.nl/global/img/3c7d77e89296.webp","kennis":[],"congress":"","summary_en":"In a double-blind randomized trial, 149 women with type 2 diabetes received dapagliflozin 5 mg or empagliflozin 10 mg daily for three months. Urinary tract infections occurred significantly less frequently with dapagliflozin compared to empagliflozin (2.5% vs 14.3%; OR 0.16; p = 0.009), with no differences in glycaemic control or renal function. The findings highlight a meaningful safety difference between these SGLT2 inhibitors and suggest that clinicians should consider individual patient risk when selecting a specific agent.","created":"2026-09-22T00:54:34Z","updated":"2026-09-22T00:54:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een gerandomiseerde, dubbelblinde trial kregen 149 vrouwen met type 2-diabetes drie maanden dapagliflozin 5 mg of empagliflozin 10 mg. De incidentie van urineweginfecties was aanzienlijk lager in de dapagliflozingroep (2,5% versus 14,3%; OR 0,16; p = 0,009), terwijl de metabole en nierfunctieparameters gelijk bleven. Deze bevindingen onderstrepen dat het veiligheidsprofiel per SGLT2-remmer verschilt en dat zorgverleners bij voorschrijven rekening moeten houden met dit verschil.","abstract_original":"BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, are widely used for glycemic control in type 2 diabetes but may affect the risk of urinary tract infection (UTI). OBJECTIVES: This study compared the incidence of UTIs among women with diabetes treated with dapagliflozin versus empagliflozin. METHODS: In this randomized, double-blind clinical trial, 149 diabetic women aged ≥ 18 years were assigned to receive dapagliflozin 5 mg (n = 79) or empagliflozin 10 mg (n = 70) daily for three months. Fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and serum creatinine (Cr) were measured at baseline and after treatment. Urinalysis and urine culture were used to confirm UTIs. Data were analyzed using SPSS version 28.0, with P < 0.05 considered statistically significant. RESULTS: The mean age was 62.7 ± 9.7 years, with no baseline differences between groups. UTIs occurred in 12 patients overall: 2 (2.5%) in the dapagliflozin group and 10 (14.3%) in the empagliflozin group (OR = 0.16; 95% CI, 0.03 - 0.74; P = 0.009). No significant intergroup differences were observed in FBS, HbA1c, or Cr levels. CONCLUSIONS: Empagliflozin was associated with a higher short-term incidence of UTIs than dapagliflozin, despite similar metabolic outcomes. Monitoring for UTIs is recommended when prescribing SGLT2 inhibitors, particularly empagliflozin. Trial Registration: This trial is registered with the Iranian Registry of Clinical Trials (IRCT20250129064554N1)."}